Chen Zhang-Hui, Yu Yan P, Tao Junyan, Liu Silvia, Tseng George, Nalesnik Michael, Hamilton Ronald, Bhargava Rohit, Nelson Joel B, Pennathur Arjun, Monga Satdarshan P, Luketich James D, Michalopoulos George K, Luo Jian-Hua
Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Department of Biostatistics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Gastroenterology. 2017 Oct;153(4):1120-1132.e15. doi: 10.1053/j.gastro.2016.12.036. Epub 2017 Feb 27.
BACKGROUND & AIMS: Human tumors and liver cancer cell lines express the product of a fusion between the first 13 exons in the mannosidase α class 2A member 1 gene (MAN2A1) and the last 6 exons in the FER tyrosine kinase gene (FER), called MAN2A1-FER. We investigated whether MAN2A1-FER is expressed by human liver tumors and its role in liver carcinogenesis.
We performed reverse transcription polymerase chain reaction analyses of 102 non-small cell lung tumors, 61 ovarian tumors, 70 liver tumors, 156 glioblastoma multiform samples, 27 esophageal adenocarcinomas, and 269 prostate cancer samples, as well as 10 nontumor liver tissues and 20 nontumor prostate tissues, collected at the University of Pittsburgh. We also measured expression by 15 human cancer cell lines. We expressed a tagged form of MAN2A1-FER in NIH3T3 and HEP3B (liver cancer) cells; Golgi were isolated for analysis. MAN2A1-FER was also overexpressed in PC3 or DU145 (prostate cancer), NIH3T3 (fibroblast), H23 (lung cancer), and A-172 (glioblastoma multiforme) cell lines and knocked out in HUH7 (liver cancer) cells. Cells were analyzed for proliferation and in invasion assays, and/or injected into flanks of severe combined immunodeficient mice; xenograft tumor growth and metastasis were assessed. Mice with hepatic deletion of PTEN were given tail-vein injections of MAN2A1-FER.
We detected MAN2A1-FER messenger RNA and fusion protein (114 kD) in the hepatocellular carcinoma cell line HUH7, as well as in liver tumors, esophageal adenocarcinoma, glioblastoma multiforme, prostate tumors, non-small cell lung tumors, and ovarian tumors, but not nontumor prostate or liver tissues. MAN2A1-FER protein retained the signal peptide for Golgi localization from MAN2A1 and translocated from the cytoplasm to Golgi in cancer cell lines. MAN2A1-FER had tyrosine kinase activity almost 4-fold higher than that of wild-type FER, and phosphorylated the epidermal growth factor receptor at tyrosine 88 in its N-terminus. Expression of MAN2A1-FER in 4 cell lines led to epidermal growth factor receptor activation of BRAF, MEK, and AKT; HUH7 cells with MAN2A1-FER knockout had significant decreases in phosphorylation of these proteins. Cell lines that expressed MAN2A1-FER had increased proliferation, colony formation, and invasiveness and formed larger (>2-fold) xenograft tumors in mice, with more metastases, than cells not expressing the fusion protein. HUH7 cells with MAN2A1-FER knockout formed smaller xenograft tumors, with fewer metastases, than control HUH7 cells. HUH7, A-172, and PC3 cells that expressed MAN2A1-FER were about 2-fold more sensitive to the FER kinase inhibitor crizotinib and the epidermal growth factor receptor kinase inhibitor canertinib; these drugs slowed growth of xenograft tumors from MAN2A1-FER cells and prevented their metastasis in mice. Hydrodynamic tail-vein injection of MAN2A1-FER resulted in rapid development of liver cancer in mice with hepatic disruption of Pten.
Many human tumor types and cancer cell lines express the MAN2A1-FER fusion, which increases proliferation and invasiveness of cancer cell lines and has liver oncogenic activity in mice.
人类肿瘤及肝癌细胞系表达一种融合产物,其由甘露糖苷酶α 2A类成员1基因(MAN2A1)的前13个外显子与FER酪氨酸激酶基因(FER)的后6个外显子融合而成,称为MAN2A1-FER。我们研究了MAN2A1-FER是否在人类肝肿瘤中表达及其在肝癌发生中的作用。
我们对匹兹堡大学收集的102例非小细胞肺癌肿瘤、61例卵巢肿瘤、70例肝肿瘤、156例多形性胶质母细胞瘤样本、27例食管腺癌及269例前列腺癌样本,以及10例非肿瘤肝组织和20例非肿瘤前列腺组织进行了逆转录聚合酶链反应分析。我们还检测了15种人类癌细胞系中的表达情况。我们在NIH3T3和HEP3B(肝癌)细胞中表达了一种带标签形式的MAN2A1-FER;分离高尔基体进行分析。MAN2A1-FER也在PC3或DU145(前列腺癌)、NIH3T3(成纤维细胞)、H23(肺癌)和A-172(多形性胶质母细胞瘤)细胞系中过表达,并在HUH7(肝癌)细胞中敲除。对细胞进行增殖和侵袭分析,和/或将细胞注射到严重联合免疫缺陷小鼠的侧腹;评估异种移植肿瘤的生长和转移情况。对PTEN肝缺失的小鼠进行尾静脉注射MAN2A1-FER。
我们在肝癌细胞系HUH7以及肝肿瘤、食管腺癌、多形性胶质母细胞瘤、前列腺肿瘤、非小细胞肺癌和卵巢肿瘤中检测到MAN2A1-FER信使核糖核酸和融合蛋白(114 kD),但在非肿瘤前列腺或肝组织中未检测到。MAN2A1-FER蛋白保留了来自MAN2A1的高尔基体定位信号肽,并在癌细胞系中从细胞质转运至高尔基体。MAN2A1-FER的酪氨酸激酶活性比野生型FER高近4倍,并使其N端酪氨酸88位的表皮生长因子受体磷酸化。在4种细胞系中表达MAN2A1-FER导致BRAF、MEK和AKT的表皮生长因子受体激活;敲除MAN2A1-FER的HUH7细胞中这些蛋白的磷酸化显著降低。表达MAN2A1-FER的细胞系增殖、集落形成和侵袭能力增强,在小鼠中形成的异种移植肿瘤比不表达融合蛋白的细胞大(>2倍),转移更多。敲除MAN2A1-FER的HUH7细胞形成的异种移植肿瘤更小,转移更少,比对照HUH7细胞少。表达MAN2A1-FER的HUH7、A-172和PC3细胞对FER激酶抑制剂克唑替尼和表皮生长因子受体激酶抑制剂卡奈替尼的敏感性约高2倍;这些药物减缓了来自MAN2A1-FER细胞的异种移植肿瘤的生长,并阻止其在小鼠中的转移。通过流体动力学尾静脉注射MAN2A1-FER导致Pten肝破坏的小鼠快速发生肝癌。
许多人类肿瘤类型和癌细胞系表达MAN2A1-FER融合蛋白,其增加了癌细胞系的增殖和侵袭能力,并在小鼠中具有肝致癌活性。